[The role of immunohistochemical methods for determining the type of treatment and prognosis of tumoral diseases].
In the last decade various immunohistochemical markers have been widely used as prognostic indices of tumors, for the most part carcinoma. These include oncogenes and oncoproteins (C-erb B-2, bcl-2), gene-suppressor p53, estrogen and progesterone receptors, proliferation markers (5-brom-2'-deoxyuridine, Ki-67, proliferation cell nuclear antigen-PCNA, cyclins, cyclin dependent kinase inhibitors), the degree of tumor angiogenesis and its modificators, adhesion molecules, factors of invasion and metastasizing. Many of these markers are independent prognostic indices and their immunohistochemical detection may be more informative than their biochemical and even molecular-biological identification. Wide use of immunohistochemistry in practical oncology makes clinical pathologist an active participant in diagnosis and treatment of tumors.
Pozharisskiĭ
K M
KM
Leenman
E E
EE
D014408:Biomarkers, Tumor; D006801:Humans; D007150:Immunohistochemistry; D009369:Neoplasms / Q000378:metabolism / Q000473:pathology* / Q000628:therapy*; D011379:Prognosis
D014408:Biomarkers, Tumor